Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - H.C. Wainwright has maintained its Buy rating and $102.00 price target on Viking Therapeutic (NASDAQ:VKTX), a $3.75 billion market cap biotech company, following the company’s second-quarter financial results released Wednesday. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $33 to $125.
Viking reported a quarterly loss of $0.58 per share, which exceeded both H.C. Wainwright’s estimate of $0.42 and the consensus estimate of $0.44 per share. The larger-than-expected loss was attributed to higher research and development expenses, which reached $60.2 million compared to the analyst’s projection of $42.04 million.
The increased R&D costs stemmed from several factors including clinical studies, manufacturing, preclinical work, stock-based compensation, and personnel expenses. Despite the wider loss, Viking ended the quarter with a strong cash position of $808 million.
H.C. Wainwright noted that Viking’s VK2735 clinical program continues to show strong progress in 2025. The firm believes this drug candidate is well-positioned within the GLP-1 market across both subcutaneous and oral formulations.
The research firm’s maintained Buy rating reflects its continued confidence in Viking’s pipeline and clinical development strategy, particularly regarding the VK2735 program.
In other recent news, Viking Therapeutics Inc . reported its financial results for the second quarter of 2025, revealing a larger-than-expected loss. The company’s earnings per share (EPS) came in at -0.58 USD, which fell short of analysts’ projections of -0.45 USD. Despite the earnings miss, there was a positive reaction from investors, indicated by a rise in the company’s stock price. This optimism is attributed to Viking Therapeutics’ ongoing developments in the obesity treatment sector. Analysts had not provided any upgrade or downgrade in this context. The company’s future growth prospects continue to draw attention, reflecting confidence in its strategic direction. These developments are part of the latest updates concerning Viking Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.